Vaccine safety questioned in South Korea: 13 people die from flu shots

Thursday, October 22nd 2020 - 08:10 UTC

Full article

Health authorities said they had no plans to suspend a program to inoculate around 19 million people for free after a preliminary investigation into six deaths

At least 13 South Koreans have died after receiving flu shots in recent days, according to official and local media reports, ramping up fears about vaccine safety even as authorities rule out a link.

Health authorities said on Wednesday they had no plans to suspend a program to inoculate around 19 million people for free after a preliminary investigation into six deaths found no direct connection to the vaccines.

No toxic substances had been found in the vaccines, and at least five of the six people investigated had underlying conditions, officials said.

Officials have reported nine deaths following flu vaccinations and the Yonhap news agency reported another four on Thursday.

The deaths, which include a 17-year-old boy and a man in his 70s, come just a week after the free flu shot program for teenagers and senior citizens was restarted.

The program was suspended for three weeks after it was discovered that some 5 million doses, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility.

South Korea's vaccines come from a variety of sources. Manufacturers include local drug makers GC Pharma, SK Bioscience and Ilyang Pharmaceutical Co, along with France's Sanofi and Britain's Glaxosmithkline. Distributors include LG Chem Ltd and Boryung Biopharma Co. Ltd., a unit of Boryung Pharm Co. Ltd.

GC Pharma, LG Chem, SK Bioscience and Boryung declined to comment. Ilyang Pharmaceutical, Sanofi and GSK could not immediately be reached for comment.

South Korea had extended its seasonal vaccine program this year to ward off any potential COVID-19 complications and overburdening hospitals over the winter.

Officials said 8.3 million people have been inoculated with the free flu vaccine since it resumed on Oct. 13, with around 350 cases of adverse reactions reported.